Quorum Review IRB Awarded Full Reaccreditation by AAHRPP
Quorum Review IRB has been awarded full reaccreditation for another three years by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
AAHRPP accredits organizations that can demonstrate they provide participant safeguards that surpass the threshold of state and federal requirements. The accreditation program utilizes a voluntary, peer-driven review and educational model.
Through the accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. AAHRPP’s standards exceed federal regulations by requiring organizations to address conflicts of interest, to provide community outreach and education, and to apply the same stringent protections to all research involving human participants.
Quorum Review was initially awarded full accreditation status from AAHRPP in April of 2006. Accredited organizations are required to renew their accreditation with AAHRPP every three years to demonstrate compliance with current AAHRPP criteria.
Since the last review by AAHRPP in 2006, Quorum has made several changes to its service offerings, including reviewing studies in Canada. Because of these changes, AAHRPP applied the Canadian Tri-Council Policy Statement guidelines in addition to U.S. guidelines in reviewing Quorum’s processes. Quorum is now one of only a few AAHRPP-accredited IRBs that is specifically accredited to review studies in Canada as well as the United States.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
